Matches in SemOpenAlex for { <https://semopenalex.org/work/W2349623012> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2349623012 abstract "Purpose To observe the inhibitive effects of E838 combined radiotherapy and chemotherapy on malignant anti-tumor and the effects on the number of bone marrow nucleated cells.Methods Establishment of mouse tumor model:to the radiotherapy group mice,2-3 mm3 tumors inoculated subcutaneously in the axillary region,to the chemotherapy group mice(NS),0.2 mL cell suspension(diluted with normal saline to the ratio of 1 to 3) were inoculated subcutaneously in forelimb armpit region.After 24 h of the establishment,the radiotherapy group mice were randomly divided into control group,radiotherapy alone group,low,middle and high dose E838 combined treatment group and drug combined irradiation group,the chemotherapy group was divided into control group,cyclophosphamide(CTX) group,low,medium,high dose E838 combined treatment group and CTX combined treatment group,CTX combined treatment group began administrating drugs(CTX 500 μg/0.2 mL),The drugs need to be injected 4 times every 2 days.In the treatment group drugs were intraperitoneal injected for 7 d,and mice in drug combined irradiation group were total-body irradiated by 1Gy 137 Cs γ-ray daily for 5 days from the 4th day of administration.On the 12 days,the mice were sacrificed and mice tumor were weighted and oncostatic rate was calculated.Results E838 combined 137 Cs γ-ray was a better tumor suppressor effect and the inhibition ratio was 65.43%,77.13% and 67.55% respectively.The inhibition ratio increased by 21.29%,6.39% and 17.55% compared with the treatment group and increased by 42.83% compared with the control group and there were significant differences(P0.001).The q values were 1.03,0.95 and 1.00 respectively which showed that there were synergistic antitumor effects combined with radiotherapy.In E838 combined CTX group,the inhibition ratio was 81.68%,82.70% and 82.14% respectively.The inhibition ratio increased by 42.9%,36.19% and 40.05% compared with the treatment group and increased by 21.0% compared with the cyclophosphamide(CTX) group and there were significant differences(P0.001).The q values were 1.07,1.04 and 1.06 respectively which showed that there were synergistic antitumor effects combined with chemotherapy.Conclusion E838 plays a great role in inhibiting malignant tumor growth in mice and E838 combined with radiotherapy and chemotherapy could enhance tumor inhibitory effect." @default.
- W2349623012 created "2016-06-24" @default.
- W2349623012 creator A5063616750 @default.
- W2349623012 date "2010-01-01" @default.
- W2349623012 modified "2023-09-23" @default.
- W2349623012 title "Inhibitive effects of E838 combined radiotherapy and chemotherapy on malignant tumor in IRM-2 mice" @default.
- W2349623012 hasPublicationYear "2010" @default.
- W2349623012 type Work @default.
- W2349623012 sameAs 2349623012 @default.
- W2349623012 citedByCount "0" @default.
- W2349623012 crossrefType "journal-article" @default.
- W2349623012 hasAuthorship W2349623012A5063616750 @default.
- W2349623012 hasConcept C105702510 @default.
- W2349623012 hasConcept C126322002 @default.
- W2349623012 hasConcept C126894567 @default.
- W2349623012 hasConcept C2776581026 @default.
- W2349623012 hasConcept C2776694085 @default.
- W2349623012 hasConcept C2776755627 @default.
- W2349623012 hasConcept C2777397205 @default.
- W2349623012 hasConcept C2778646069 @default.
- W2349623012 hasConcept C2779429289 @default.
- W2349623012 hasConcept C2780007613 @default.
- W2349623012 hasConcept C509974204 @default.
- W2349623012 hasConcept C71924100 @default.
- W2349623012 hasConceptScore W2349623012C105702510 @default.
- W2349623012 hasConceptScore W2349623012C126322002 @default.
- W2349623012 hasConceptScore W2349623012C126894567 @default.
- W2349623012 hasConceptScore W2349623012C2776581026 @default.
- W2349623012 hasConceptScore W2349623012C2776694085 @default.
- W2349623012 hasConceptScore W2349623012C2776755627 @default.
- W2349623012 hasConceptScore W2349623012C2777397205 @default.
- W2349623012 hasConceptScore W2349623012C2778646069 @default.
- W2349623012 hasConceptScore W2349623012C2779429289 @default.
- W2349623012 hasConceptScore W2349623012C2780007613 @default.
- W2349623012 hasConceptScore W2349623012C509974204 @default.
- W2349623012 hasConceptScore W2349623012C71924100 @default.
- W2349623012 hasLocation W23496230121 @default.
- W2349623012 hasOpenAccess W2349623012 @default.
- W2349623012 hasPrimaryLocation W23496230121 @default.
- W2349623012 hasRelatedWork W1979663197 @default.
- W2349623012 hasRelatedWork W2357444572 @default.
- W2349623012 hasRelatedWork W2358562771 @default.
- W2349623012 hasRelatedWork W2359170993 @default.
- W2349623012 hasRelatedWork W2362167184 @default.
- W2349623012 hasRelatedWork W2370809356 @default.
- W2349623012 hasRelatedWork W2376365909 @default.
- W2349623012 hasRelatedWork W2378391618 @default.
- W2349623012 hasRelatedWork W2378628095 @default.
- W2349623012 hasRelatedWork W2381325625 @default.
- W2349623012 hasRelatedWork W2381822282 @default.
- W2349623012 hasRelatedWork W2387930885 @default.
- W2349623012 hasRelatedWork W2388762021 @default.
- W2349623012 hasRelatedWork W2389153125 @default.
- W2349623012 hasRelatedWork W2389789178 @default.
- W2349623012 hasRelatedWork W2392213084 @default.
- W2349623012 hasRelatedWork W2392475984 @default.
- W2349623012 hasRelatedWork W2491501156 @default.
- W2349623012 hasRelatedWork W3030508989 @default.
- W2349623012 hasRelatedWork W3031114079 @default.
- W2349623012 isParatext "false" @default.
- W2349623012 isRetracted "false" @default.
- W2349623012 magId "2349623012" @default.
- W2349623012 workType "article" @default.